Supported by $1 billion from a recent equity offering, Zealand Pharma A/S is planning to increase investment in its obesity portfolio and broaden its partnerships with other pharmaceutical companies. The Denmark-based company, which was founded in 1998 to produce peptide-based medicines, has already invented 10 medicines, two of which are on the market. Going forward it will progress three late-stage clinical candidates and invest in new assets.
